Wilson's disease and hemochromatosis

Adolescent Medicine Clinics

Volumn 15, Issue 1, 2004, Pages 175-194

  Neimark, Ezequiel ^a   Schilsky, Michael L ^b   Shneider, Benjamin L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; PENICILLAMINE; TETRATHIOMOLYBDENATE; TRIENTINE; UNCLASSIFIED DRUG; ZINC;

ADOLESCENT; BONE MARROW SUPPRESSION; CLINICAL FEATURE; COPPER METABOLISM; DIAGNOSTIC PROCEDURE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC RISK; HEALTH SURVEY; HEMOCHROMATOSIS; HOMEOSTASIS; HUMAN; LABORATORY TEST; LIVER TRANSPLANTATION; LUPUS ERYTHEMATOSUS; MEDICAL EXAMINATION; NEPHROSIS; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SKIN TOXICITY; TREATMENT OUTCOME; WILSON DISEASE;

EID: 3142775596     PISSN: 15473368     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.admecli.2003.11.011     Document Type: Review

References (103)

1. Culotta VC. Disorders of copper transport. In: Scriver CR, Sly WS, Valle D, Gitlin JD, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 2001. p. 3105-27.
2. Sternlieb I. Wilson's disease [review]. Clin Liver Dis 2000;4:229-39, viii- ix.
3. Hamza I, Gitlin JD. Copper metabolism and the liver. In: Arias IM, Boyer JL, Chisari FV, Fausto N, Schachter D, Schafritz DA, editors. The liver: biology and pathology. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 331-43.
4. Hung IH, Suzuki M, Yamaguchi Y, et al. Biochemical characterization of the Wilson disease protein and functional expression in the yeast Saccharomyces cerevisiae. J Biol Chem 1997;272:21461-6.
5. Schaefer M, Hopkins RG, Failla ML, Gitlin JD. Hepatocyte-specific localization and copperdependent trafficking of the Wilson's disease protein in the liver. Am J Physiol 1999;276:G639-46.
6. Terada K, Schilsky ML, Miura N, Sugiyama T. ATP7B (WND) protein. Int J Biochem Cell Biol 1998;30:1063-7.
7. Payne AS, Kelly EJ, Gitlin JD. Functional expression of the Wilson disease protein reveals mislocalization and impaired copper-dependent trafficking of the common H1069Q mutation. Proc Natl Acad Sci U S A 1998;95:10854-9.
8. Sternlieb I. Copper and the liver. Gastroenterology 1980;78:1615-28.
9. Goldfischer S, Popper H, Sternlieb I. The significance of variations in the distribution of copper in liver disease. Am J Pathol 1980;99:715-30.
10. Wilson S. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912;34:295.
11. Scheinberg IH. Wilson's disease. In: Smith L, editor. Major problems in internal medicine. Philadelphia: WB Saunders; 1984.
12. Sokol RJ, Devereaux M, Mierau GW, Hambidge KM, Shikes RH. Oxidant injury to hepatic mitochondrial lipids in rats with dietary copper overload. Modification by vitamin E deficiency. Gastroenterology 1990;99:1061-71.
13. Bearn A. A genetical analysis of thirty families with Wilson's disease (hepatolenticular degeneration). Ann Hum Genet 1960;24:33.
14. Shah AB, Chernov I, Zhang HT, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet 1997;61:317-28.
15. Richard VS, Harris VK, Shankar V, Loganathan G, Chandy GM. Clinical manifestations and survival pattern of Wilson's disease. Natl Med J India 2000;13:301-3.
16. Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: clinical presentation and use of prognostic index. Gut 1986;27:1377-81.
17. Schilsky ML. Diagnosis and treatment of Wilson's disease. Pediatr Transplant 2002;6:15-9.
18. Sternlieb I. Wilson's disease and pregnancy. Hepatology 2000;31:531-2.
19. Erkan T, Aktuglu C, Gulcan EM, et al. Wilson disease manifested primarily as amenorrhea and accompanying thrombocytopenia. J Adolesc Health 2002;31:378-80.
20. Emre S, Atillasoy EO, Ozdemir S, et al. Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation 2001;72:1232-6.
21. Hoogenraad T. Wilson's disease. In: Warlow CP, editor. Major problems in neurology. London: WB Saunders; 1996.
22. Liu M, Cohen EJ, Brewer GJ, Laibson PR. Kayser-Fleischer ring as the presenting sign of Wilson disease. Am J Ophthalmol 2002;133:832-4.
23. Hamlyn AN, Gollan JL, Douglas AP, Sherlock S. Fulminant Wilson's disease with haemolysis and renal failure: copper studies and assessment of dialysis regimens. BMJ 1977;2:660-2.
24. Roche-Sicot J, Benhamou JP. Acute intravascular hemolysis and acute liver failure associated as a first manifestation of Wilson's disease. Ann Intern Med 1977;86:301-3.
25. Schilsky ML. Wilson disease: genetic basis of copper toxicity and natural history. Semin Liver Dis 1996;16:83-95.
26. Martins da Costa C, Baldwin D, Portmann B, et al. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology 1992;15:609-15.
27. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver 2003;23:139-42.
28. Yuce A, Kocak N, Demir H, et al. Evaluation of diagnostic parameters of Wilson's disease in childhood. Indian J Gastroenterol 2003;22:4-6.
29. McDonald JA, Snitch P, Painter D, et al. Striking variability of hepatic copper levels in fulminant hepatic failure. J Gastroenterol Hepatol 1992;7:396-8.
30. Ferenci P, Jessner W, Munda-Steindl P, Wrba F. Diagnostic value of quantitative copper determination in liver biopsy samples in patients with Wilson disease. Hepatology 2002;36:338A.
31. Steindl P, Ferenci P, Dienes HP, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997;113:212-8.
32. Aisen AM, Martel W, Gabrielsen TO, et al. Wilson disease of the brain: MR imaging. Radiology 1985;157:137-41.
33. Caca K, Ferenci P, Kuhn HJ, et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol 2001;35:575-81.
34. Cox DW. Molecular advances in Wilson disease. Prog Liver Dis 1996;14:245-64.
35. Schilsky ML. Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation? Curr Gastroenterol Rep 2001;3:54-9.
36. Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003;60:379-85.
37. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998;132:264-78.
38. Brewer GJ, Dick RD, Johnson VD, Fink JK, Kluin KJ, Daniels S. Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years. J Lab Clin Med 2001;137:191-8.
39. Askari FB, Brewer GJ. Reversal of hepatic decompensation following treatment of Wilson's disease can preclude the need for liver transplantation. Hepatology 2000;32:334A.
40. Schilsky ML. Trientine and zinc combination therapy for the treatment of Wilson's disease. Hepatology 2001;34:210A.
41. Durand F, Bernuau J, Giostra E, et al. Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine. Gut 2001;48:849-52.
42. Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome. Hepatology 1994;19:583-7.
43. Schilsky ML, Scheinberg IH, Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 1991;100:762-7.
44. Brewer GJ, Johnson VD, Dick RD, et al. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. Hepatology 2000;31:364-70.
45. Scheinberg IH, Sternlieb I. Pregnancy in penicillamine-treated patients with Wilson's disease. N Engl J Med 1975;293:1300-2.
46. Walshe JM. Pregnancy in Wilson's disease. Q J Med 1977;46:73-83.
47. Shimono N, Ishibashi H, Ikematsu H, et al. Fulminant hepatic failure during perinatal period in a pregnant woman with Wilson's disease. Gastroenterol Jpn 1991;26:69-73.
48. Bunke H, Cario WR, Schneider M. Variations in the composition of breast milk in Wilson's disease. Kinderarztl Prax 1989;57:89-92.
49. Bax RT, Hassler A, Luck W, et al. Cerebral manifestation of Wilson's disease successfully treated with liver transplantation. Neurology 1998;51:863-5.
50. Lui CC, Chen CL, Cheng YF, Lee TY. Recovery of neurological deficits in a case of Wilson's disease after liver transplantation. Transplant Proc 1998;30:3324-5.
51. Stracciari A, Tempestini A, Borghi A, Guarino M. Effect of liver transplantation on neurological manifestations in Wilson disease. Arch Neurol 2000;57:384-6.
52. Sutcliffe RP, Maguire DD, Muiesan P, et al. Liver transplantation for Wilson's disease: longterm results and quality-of-life assessment. Transplantation 2003;75:1003-6.
53. Komatsu H, Fujisawa T, Inui A, et al. Hepatic copper concentration in children undergoing living related liver transplantation due to Wilsonian fulminant hepatic failure. Clin Transplant 2002;16:227-32.
54. Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 2001;120:718-25.
55. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999;116:193-207.
56. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
57. Sokol R. Copper and iron storage diseases. In: Suchy F, Balistreri W, editors. Liver disease in children. 2nd edition. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 595-640.
58. Finch C. Regulators of iron balance in humans. Blood 1994;84:1697-702.
59. Philpott CC. Molecular aspects of iron absorption: insights into the role of HFE in hemochromatosis. Hepatology 2002;35:993-1001.
60. Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Curr Top Cell Regul 1997;35:1-19.
61. Cox TM, Peters TJ. In vitro studies of duodenal iron uptake in patients with primary and secondary iron storage disease. Q J Med 1980;49:249-57.
62. Cox TM, Peters TJ. Uptake of iron by duodenal biopsy specimens from patients with irondeficiency anaemia and primary haemochromatosis. Lancet 1978;1:123-4.
63. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol 2002;64:663-80.
64. Frazer DM, Wilkins SJ, Becker EM, et al. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 2002;123:835-44.
65. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001;98:8780-5.
66. Bacon BR. Hemochromatosis: pathophysiologic mechanisms. Presented at American Association for the Study of Liver Diseases Postgraduate Course. Boston (MA), November 2, 2002. p. 157-162.
67. Parkkila S, Waheed A, Britton RS, et al. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci U S A 1997;94:2534-9.
68. Parkkila S, Niemela O, Britton RS, et al. Molecular aspects of iron absorption and HFE expression. Gastroenterology 2001;121:1489-96.
69. Trinder D, Olynyk JK, Sly WS, Morgan EH. Iron uptake from plasma transferrin by the duodenum is impaired in the Hfe knockout mouse. Proc Natl Acad Sci U S A 2002;99:5622-6.
70. Rolfs A, Bonkovsky HL, Kohlroser JG, et al. Intestinal expression of genes involved in iron absorption in humans. Am J Physiol Gastrointest Liver Physiol 2002;282:G598-607.
71. Zoller H, Pietrangelo A, Vogel W, Weiss G. Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet 1999;353:2120-3.
72. Dupic F, Fruchon S, Bensaid M, et al. Inactivation of the hemochromatosis gene differentially regulates duodenal expression of iron-related mRNAs between mouse strains. Gastroenterology 2002;122:745-51.
73. Fleming RE, Migas MC, Zhou X, et al. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1. Proc Natl Acad Sci U S A 1999;96:3143-8.
74. Simon M, Bourel M, Genetet B, Fauchet R. Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977;297:1017-21.
75. Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-8.
76. Waheed A, Parkkila S, Zhou XY, et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci U S A 1997;94:12384-9.
77. Distante S, Berg JP, Lande K, Haug E, Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 2000;47:575-9.
78. Crawford DH, Jazwinska EC, Cullen LM, Powell LW. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998;114:1003-8.
79. Rhodes DA, Raha-Chowdhury R, Cox TM, Trowsdale J. Homozygosity for the predominant Cys282Tyr mutation and absence of disease expression in hereditary haemochromatosis. J Med Genet 1997;34:761-4.
80. Adams PC. Abstract No 73. Presented at World Congress on Iron Metabolism: BioIron 1999. May 23-28, 1999.
81. Jouanolle A. Abstract No 254. Presented at World Congress on Iron Metabolism: BioIron 1999. May 23-28, 1999.
82. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
83. Haddy TB, Castro OL, Rana SR. Hereditary hemochromatosis in children, adolescents, and young adults. Am J Pediatr Hematol Oncol 1988;10:23-34.
84. Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997;92:784-9.
85. A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium. Gut 1997;41:841-4.
86. Jouanolle AM, Gandon G, Jezequel P, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:251-2.
87. Edwards CQ, Griffen LM, Goldgar D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318:1355-62.
88. McLaren CE, McLachlan GJ, Halliday JW, et al. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology 1998;114:543-9.
89. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994;154:769-76.
90. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999;130:953-62.
91. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998;115:929-36.
92. Powell LW. Broadsheet number 54. Hereditary hemochromatosis. Pathology 2000;32:24-36.
93. Brunt EM, Olynyk JK, Britton RS, et al. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am J Gastroenterol 2000;95:1788-93.
94. Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol 1999;94:1593-600.
95. Tavill AS. Screening for hemochromatosis: phenotyping or genotyping or both? Am J Gastroenterol 1999;94:1430-3.
96. Escobar GJ, Heyman MB, Smith WB, Thaler MM. Primary hemochromatosis in childhood. Pediatrics 1987;80:549-54.
97. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-8.
98. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-6.
99. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
100. Deugnier YM, Guyader D, Crantock L, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993;104:228-34.
101. De Gobbi M, Roetto A, Piperno A, et al. Natural history of juvenile haemochromatosis. Br J Haematol 2002;117:973-9.
102. Roetto A. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33(1):21-2.
103. Cazzola M, Cerani P, Rovati A, et al. Juvenile genetic hemochromatosis is clinically and genetically distinct from the classical HLA-related disorder. Blood 1998;92:2979-81.